JP7763489B2 - Cdk阻害剤及び医薬品としてのそれらの使用 - Google Patents

Cdk阻害剤及び医薬品としてのそれらの使用

Info

Publication number
JP7763489B2
JP7763489B2 JP2022515905A JP2022515905A JP7763489B2 JP 7763489 B2 JP7763489 B2 JP 7763489B2 JP 2022515905 A JP2022515905 A JP 2022515905A JP 2022515905 A JP2022515905 A JP 2022515905A JP 7763489 B2 JP7763489 B2 JP 7763489B2
Authority
JP
Japan
Prior art keywords
alkyl
fluoro
carboxamide
isopropyl
cyclohexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022515905A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548568A (ja
JP2022548568A5 (cg-RX-API-DMAC7.html
Inventor
ルー,リアン
シェティ,ルパ
ポール コームズ,アンドリュー
ダイ,チャオフォン
アンドリュー レアル,ラウル
ラソール バーシュ,クレア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prelude Therapeutics Inc
Original Assignee
Prelude Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prelude Therapeutics Inc filed Critical Prelude Therapeutics Inc
Publication of JP2022548568A publication Critical patent/JP2022548568A/ja
Publication of JP2022548568A5 publication Critical patent/JP2022548568A5/ja
Application granted granted Critical
Publication of JP7763489B2 publication Critical patent/JP7763489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022515905A 2019-09-11 2020-09-11 Cdk阻害剤及び医薬品としてのそれらの使用 Active JP7763489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962898839P 2019-09-11 2019-09-11
US62/898,839 2019-09-11
US202063005577P 2020-04-06 2020-04-06
US63/005,577 2020-04-06
PCT/US2020/050326 WO2021050824A1 (en) 2019-09-11 2020-09-11 Cdk inhibitors and their use as pharmaceuticals

Publications (3)

Publication Number Publication Date
JP2022548568A JP2022548568A (ja) 2022-11-21
JP2022548568A5 JP2022548568A5 (cg-RX-API-DMAC7.html) 2023-09-15
JP7763489B2 true JP7763489B2 (ja) 2025-11-04

Family

ID=74850746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022515905A Active JP7763489B2 (ja) 2019-09-11 2020-09-11 Cdk阻害剤及び医薬品としてのそれらの使用

Country Status (11)

Country Link
US (3) US20220324830A1 (cg-RX-API-DMAC7.html)
EP (1) EP4028005A4 (cg-RX-API-DMAC7.html)
JP (1) JP7763489B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220079851A (cg-RX-API-DMAC7.html)
CN (1) CN114786673A (cg-RX-API-DMAC7.html)
AU (1) AU2020345950A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022004327A2 (cg-RX-API-DMAC7.html)
CA (1) CA3153531A1 (cg-RX-API-DMAC7.html)
IL (1) IL291191A (cg-RX-API-DMAC7.html)
MX (1) MX2022002946A (cg-RX-API-DMAC7.html)
WO (1) WO2021050824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020345950A1 (en) 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
CN114605390B (zh) * 2020-12-04 2024-08-16 上海凌达生物医药有限公司 具有cdk激酶抑制活性的化合物、其药物组合物和用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术(石家庄)有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术(石家庄)有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
US20230144528A1 (en) * 2021-09-30 2023-05-11 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
AU2022362075A1 (en) * 2021-10-14 2024-05-09 Prelude Therapeutics Incorporated Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2025189114A1 (en) 2024-03-08 2025-09-12 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2026024933A1 (en) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
CN119638640A (zh) * 2024-12-10 2025-03-18 杭州亦宁医药技术有限公司 一种5-溴-2-甲基-3-异丙基-吲唑的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516710A (ja) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド ピリジン系cdk9キナーゼ阻害薬
WO2016197078A1 (en) 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
JP2017503813A (ja) 2014-01-14 2017-02-02 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリール及びそれらの使用
JP2017523214A (ja) 2014-08-05 2017-08-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環キナーゼ阻害剤
JP2018535931A (ja) 2015-09-30 2018-12-06 レ ラボラトワール セルヴィエ 二重DYRK1/CLK1阻害剤としての新規イミダゾ[4,5−b]ピリジン誘導体
JP2019521994A (ja) 2016-07-22 2019-08-08 アクロ バイオサイエンス インク. ネクローシス阻害剤であるヘテロアリール化合物、その組成物及び用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070354A2 (en) * 2006-10-31 2008-06-12 Smithkline Beecham Corporation 5- and 6- substituted benzimidazole thiophene compounds
CA2719059C (en) 2008-03-27 2016-05-17 Nestec S.A. Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates
US8435980B2 (en) * 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US9440952B2 (en) * 2013-03-04 2016-09-13 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2015108881A1 (en) * 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TR201909286T4 (tr) * 2015-06-29 2019-07-22 Astrazeneca Ab CDK9 inhibitörleri olarak polisiklik amid türevleri.
US10815432B2 (en) 2015-09-22 2020-10-27 Hindustan Petroleum Corporation Limited Additive and a catalyst composition comprising the additive for FCC process
AU2020345950A1 (en) * 2019-09-11 2022-03-31 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
US20230265083A1 (en) * 2020-08-10 2023-08-24 Prelude Therapeutics Incorporated Heterocycle CDK Inhibitors And Their Use Thereof
EP4214213A1 (en) * 2020-09-21 2023-07-26 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
IL316942A (en) * 2020-12-18 2025-01-01 Prelude Therapeutics Inc CDK inhibitors and their use as drugs
US20230144528A1 (en) * 2021-09-30 2023-05-11 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
AU2022362075A1 (en) * 2021-10-14 2024-05-09 Prelude Therapeutics Incorporated Crystalline forms of a substituted benzimidazole acting as as cdk9 inhibitor and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516710A (ja) 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド ピリジン系cdk9キナーゼ阻害薬
JP2017503813A (ja) 2014-01-14 2017-02-02 ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. ヘテロアリール及びそれらの使用
JP2017523214A (ja) 2014-08-05 2017-08-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環キナーゼ阻害剤
WO2016197078A1 (en) 2015-06-05 2016-12-08 Syros Pharmaceuticals, Inc. Compounds for the modulation of myc activity
JP2018535931A (ja) 2015-09-30 2018-12-06 レ ラボラトワール セルヴィエ 二重DYRK1/CLK1阻害剤としての新規イミダゾ[4,5−b]ピリジン誘導体
JP2019521994A (ja) 2016-07-22 2019-08-08 アクロ バイオサイエンス インク. ネクローシス阻害剤であるヘテロアリール化合物、その組成物及び用途

Also Published As

Publication number Publication date
US20210070761A1 (en) 2021-03-11
IL291191A (en) 2022-05-01
KR20220079851A (ko) 2022-06-14
JP2022548568A (ja) 2022-11-21
CN114786673A (zh) 2022-07-22
CA3153531A1 (en) 2021-03-18
MX2022002946A (es) 2022-06-14
EP4028005A1 (en) 2022-07-20
AU2020345950A1 (en) 2022-03-31
US12486277B2 (en) 2025-12-02
US11673893B2 (en) 2023-06-13
US20220324830A1 (en) 2022-10-13
BR112022004327A2 (pt) 2022-05-31
US20230242543A1 (en) 2023-08-03
EP4028005A4 (en) 2023-09-20
WO2021050824A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US12486277B2 (en) CDK inhibitors and their use as pharmaceuticals
US11078205B2 (en) Selective inhibitors of protein arginine methlytransferase 5 (PRMT5)
KR20230152654A (ko) 키나아제 억제제로서의 인다졸 화합물
JP7328218B2 (ja) タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤
WO2023192416A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
IL303779A (en) CDK inhibitors and their use as drugs
JP2025525433A (ja) インダゾール化合物
WO2024211346A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2022035799A1 (en) Heterocycle cdk inhibitors and their use thereof
US11622970B2 (en) BCL-2 inhibitors and their use as pharmaceuticals
WO2023056441A1 (en) Cdk inhibitors and their use as pharmaceuticals
WO2024086789A2 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
WO2025038815A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
JP2025510738A (ja) 多型化合物及びその使用
EA049578B1 (ru) Ингибиторы cdk (циклин-зависимой киназы) и их применение в фармацевтических препаратах
WO2024216249A1 (en) Cdk inhibitors and their use as pharmaceuticals
HK40067540A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CN115698024A (zh) 作为髓系细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物
HK40031042A (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
HK40031042B (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA040066B1 (ru) Селективные ингибиторы протеин-аргинин-метилтрансферазы 5 (prmt5)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240813

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250821

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251015

R150 Certificate of patent or registration of utility model

Ref document number: 7763489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150